Personal Injury Lawyer
Personal Injury Attorney Firm Profile Attorney Profiles News and Events Contact Us
Information and Help

Wage and Overtime

Asbestos Lawyers

Personal Injury

Jury Finds Johnson & Johnson Failed to Warn of Levaquin Risks

Today a federal court jury in Minneapolis, Minnesota determined that Johnson & Johnson failed to adequately warn of the risks of tendon rupture in users of its antibiotic, Levaquin. This is the first trial involving claims that Levaquin carries a higher risk of tendon damage and rupture. There are approximately 2,600 Levaquin lawsuits on file.
The jury assigned 75% of the liability to Otho-McNeil-Janssen (Johnson & Johnson's pharmaceutical unit), 10% to the Plaintiff and 15% to Plaintiff's doctor. The jury is still considering Plaintiff's claim for punitive damages.
Levaquin, an antibiotic belonging to the class of antibiotics called fluoroquinolones, is marketed in the United States by Johnson & Johnson and its pharmaceutical unit, Ortho-McNeil-Janssen. In 2008, the FDA required that Levaquin and other fluoroquinolones carry a warning that these drugs carried an increased risk of tendon damage and tendon rupture.
Plaintiffs allege that Johnson & Johnson aggressively marketed the drug, prescribed more than 430 million times worldwide, and downplayed the risk of tendon damage and tendon rupture. J&J denies that Levaquin caused Plaintiff's injury or that it concealed any relevant safety information.

Million Dollar Advocates Forum

Public Citizen

Americas Top 100 Attorneys

Best D 2017

Attorney Web Design The information on this website is for general information purposes only. Nothing on this or associated pages, documents, comments, answers, emails, or other communications should be taken as legal advice for any individual case or situation. This information on this website is not intended to create, and receipt or viewing of this information does not constitute, an attorney-client relationship.